Diabetic Peripheral Neuropathy Market Size and Growth Forecast for Businesses 2025–2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Diabetic Peripheral Neuropathy Market?

The market for diabetic peripheral neuropathy has experienced robust expansion in recent times. Forecasts indicate it will expand from $3.51 billion in 2024 to reach $3.83 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 9.1%. This historical growth can be ascribed to factors such as an expanding elderly population, the increasing prevalence of diabetes, escalating healthcare spending, heightened understanding of diabetic complications, and advancements in healthcare infrastructure.

The diabetic peripheral neuropathy market is projected to experience substantial growth in the coming years, reaching $5.39 billion by 2029 with a compound annual growth rate (CAGR) of 8.9%. This expansion during the forecast period can be attributed to several factors, including an increase in sedentary lifestyles, heightened government initiatives and funding, a rising prevalence of neuropathy risk factors, improved diagnostic accuracy, and increasing support for early detection and prevention. Significant trends expected during this period encompass advancements in diagnostic technologies, technological progress in treatment options, greater investment in research and development, the development of minimally invasive procedures, and an intensified focus on collaborative research and development.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21170&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Diabetic Peripheral Neuropathy Industry?

The diabetic peripheral neuropathy market is expected to expand going forward, propelled by an increase in obesity-related health issues. Obesity is a medical condition marked by excessive body fat accumulation that can compromise health and elevate the susceptibility to various chronic diseases. The rise in health problems linked to obesity is attributed to heightened awareness, shifts in lifestyle, and a growing demand for both preventive and curative solutions, leading to increased healthcare needs. Diabetic peripheral neuropathy is beneficial for obesity management, offering crucial insights into nerve damage stemming from obesity-related conditions. This guidance facilitates targeted interventions aimed at enhancing overall patient well-being and quality of life. For instance, in March 2024, data from the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations responsible for global public health, reported that in 2022, 43% of adults aged 18 and over were categorized as overweight, with 16% experiencing obesity. Additionally, 37 million children under the age of 5 were overweight. Among children and adolescents aged 5 to 19 years, over 390 million were overweight, including 160 million who were affected by obesity. Thus, the escalating incidence of obesity-related health issues is fostering growth in the diabetic peripheral neuropathy market.

What Are The Key Segments In The Diabetic Peripheral Neuropathy Market?

The diabetic peripheral neuropathymarket covered in this report is segmented –

1) By Disease: Type 2 Diabetic Peripheral Neuropathy; Type 1 Diabetic Peripheral Neuropathy

2) By Treatment: Pain Management Drugs; Gene Therapies

3) By Therapy: Antidepressants; Anticonvulsants

4) By Patient Population: Adult Patients; Geriatric Patients

Subsegments:

1) By Type 2 Diabetic Peripheral Neuropathy: Sensory Neuropathy; Motor Neuropathy; Autonomic Neuropathy

2) By Type 1 Diabetic Peripheral Neuropathy: Distal Symmetric Neuropathy; Mononeuropathy; Polyradiculopathy

What Are The Major Trends Driving The Growth Of The Diabetic Peripheral Neuropathy Market?

Major companies operating in the diabetic peripheral neuropathy market are increasingly focusing on technological innovations, such as NaV1.8 pain signal inhibitors, aiming to offer patients advanced, non-opioid treatments that improve pain management and their overall quality of life. A NaV1.8 pain signal inhibitor is a specialized drug designed to block the NaV1.8 sodium channel, which is a key mediator of pain signals within sensory neurons, thereby providing relief from acute and neuropathic pain without the need for opioids. For instance, in April 2024, Vertex Pharmaceuticals Incorporated, a US-based biotech company, announced significant advancements in its suzetrigine pain program, including the initiation of a Phase 3 pivotal program specifically for treating pain associated with diabetic peripheral neuropathy (DPN). Suzetrigine, which is a selective NaV1.8 pain signal inhibitor, has demonstrated promising results in earlier studies and recently received breakthrough therapy designation from the Food and Drug Administration (FDA), a US-based federal agency, for diabetic Peripheral Neuropathy (DPN) pain management.

Who Are The Prominent Global Companies Shaping The Diabetic Peripheral Neuropathy Market?

Major companies operating in the diabetic peripheral neuropathy market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc., Eli Lilly and Company, Astellas Pharma Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Sun Pharmaceutical Industries Limited, Lupin Pharmaceuticals Inc., Chemie Grünenthal GmbH, Alkem Laboratories Limited, Acorda Therapeutics Inc., Mitsubishi Tanabe Pharma Corporation, NeuroMetrix Inc., Regenacy Pharmaceuticals Inc., Helixmith Co. Ltd., Aptinyx Inc., WinSanTor Inc., Sonnet BioTherapeutics Holdings Inc., OLYS Pharma Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/diabetic-peripheral-neuropathy-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Diabetic Peripheral Neuropathy Market?

North America was the largest region in the diabetic peripheral neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic peripheral neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Diabetic Peripheral Neuropathy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21170&type=smp

Browse Through More Reports Similar to the Global Diabetic Peripheral Neuropathy Market 2025, By The Business Research Company

Diabetic Neuropathy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report

Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

Digital Diabetes Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/digital-diabetes-management-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795